Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia

Blood

Volumn 105, Issue 1, 2005, Pages 131-138

  Rauova, Lubica ^b   Poncz, Mortimer ^b   McKenzie, Steven E ^b   Reilly, Michael P ^b   Arepally, Gowthami ^b   Weisel, John W ^b   Nagaswami, Chandrasekaran ^b   Cines, Douglas B ^b   Sachais, Bruce S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FC RECEPTOR; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; PENTASACCHARIDE; THROMBOCYTE FACTOR 4;

ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 11144238284     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-04-1544     Document Type: Article

References (47)

1. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci. 1993;305:208-215.
2. Arepally G, Cines DB. Heparin-induced thrombocytopenia and thrombosis. Clin Rev Allergy Immunol. 1998;16:237-247.
3. Warkentin TE. Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med. 1999;50:129-147.
4. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
5. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Annu Rev Med. 1989;40:31-44.
6. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
7. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol. 1997;56:12-16.
8. Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol. 1993;84:322-328.
9. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95-96.
10. Zucker MB, Katz IR. Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med. 1991;198:693-702.
11. Reilly MP, Taylor SM, Hartman NK, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood. 2001;98:2442-2447.
12. Arepally G, Reynolds C, Tomaski A, et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1995;104:648-654.
13. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost. 1995;73:21-28.
14. Andersen GP. Insights into heparin-induced thrombocytopenia. Br J Haematol. 1992;80:504-508.
15. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol. 1989;73:235-240.
16. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988;72:925-930.
17. Cohen M. Heparin-induced thrombocytopenia and the clinical use of low molecular weight heparins in acute coronary syndromes. Semin Hematol. 1999;36:33-36.
18. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95:1242-1246.
19. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med. 1996;128:376-383.
20. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99:2530-2536.
21. Home MK III, Hutchison KJ. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol. 1998;58:24-30.
22. Horsewood P, Warkentin TE, Hayward CP, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95:161-167.
23. Li ZQ, Liu W, Park KS, et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood. 2002;99:1230-1236.
24. Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood. 1998;92:3250-3259.
25. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anti-coagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost. 1995;74:886-892.
26. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71:247-251.
27. Arepally GM, Kamei S, Park KS, et al. Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood. 2000;95:1533-1540.
28. Park KS, Rifat S, Eck H, Adachi K, Surrey S, Poncz M. Biologic and biochemic properties of recombinant platelet factor 4 demonstrate identity with the native protein. Blood. 1990;75:1290-1295.
29. Zhang X, Chen L, Bancroft DP, Lai CK, Maione TE. Crystal structure of recombinant human platelet factor 4. Biochemistry. 1994;33:8361-8366.
30. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989;77:51-59.
31. Fowler WE, Erickson HP. Trinodular structure of fibrinogen: confirmation by both shadowing and negative stain electron microscopy. J Mol Biol. 1979;134:241-249.
32. Veklich YI, Gorkun OV, Medved LV, Nieuwenhuizen W, Weisel JW. Carboxyl-terminal portions of the alpha chains of fibrinogen and fibrin: localization by electron microscopy and the effects of isolated alpha C fragments on polymerization. J Biol Chem. 1993;268:13577-13585.
33. Weisel JW, Stauffacher CV, Bullitt E, Cohen C. A model for fibrinogen: domains and sequence. Science. 1985;230:1388-1391.
34. Lortat-Jacob H, Grosdidier A, Imberty A. Structural diversity of heparan sulfate binding domains inchemokines. Proc Natl Acad Sci USA. 2002;99:1229-1234.
35. Gerber N, Lowman H, Artis DR, Eigenbrot C. Receptor-binding conformation of the "ELR" motif of IL-8: x-ray structure of the L5C/H33C variant at 2.35 A resolution. Proteins. 2000;38:361-367.
36. Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med. 2001;138:22-31.
37. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associasted thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71:247-251.
38. Bock PE, Uuscombe M, Marshall SE, Pepper DS, Holbrook JJ. The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J. 1980;191:769-776.
39. Home III MK, Alkins BR. Platelet binding of IgG from patients with heparin-induced thrombocytopenia. J Lab Clin Med. 1996;127:435-442.
40. Bachmann MF, Hengartner H, Zinkemagel RM. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur J Immunol. 1995;25:3445-3451.
41. Bachmann MF, Zinkemagel RM, Oxenius A. Immune responses in the absence of costimulation: viruses know the trick. J Immunol. 1998;161:5791-5794.
42. Cines DB, Kaywin P, Bina M, Tomaski A, Schreiber AD. Heparin-associated thrombocytopenia. N Engl J Med. 1980;303:788-795.
43. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691-3699.
44. Suh JS, Malik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol. 1997;54:196-201.
45. Fehr T, Bachmann MF, Bucher E, et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med. 1997;185:1785-1792.
46. Greinacher A, Michels I, Liebenhoff U, Presek P, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol. 1993;84:711-716.
47. Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J. 1983;209:455-460.